Skip to main content
Logo Logo Logo
  • Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Global English
    • Austria Deutsch
    • Belgium Nederlands Français
    • Brazil Português
    • Canada Français English
    • Denmark Dansk
    • France Français
    • Germany Deutsch
    • Ireland English
    • Italy Italiano
    • Japan 日本語
    • Luxembourg Français Deutsch
    • Netherlands Nederlands
    • Portugal Português
    • Spain Español
    • Sweden Svenska
    • Switzerland Français Deutsch Italiano
    • Taiwan 繁體中文
    • United Kingdom English
  • Our Company
    • About Alnylam
    • Leadership
    • Diversity, Equity & Inclusion
    • Patient Access Philosophy
    • Corporate Responsibility
    • Alnylam Challengers
    • Transparency
    • Grants & Giving
    • Investigator Initiated Studies (IIS)
  • Our Science
    • The Science of RNAi
    • Delivery Platforms
    • Making Our Medicines
    • Therapeutic Areas
    • Pipeline
    • Clinical Trials
    • Scientific Advisory Board
    • Intellectual Property
    • Capella (Scientific Presentations)
  • Our Products
    • Product Listing
  • Our News
    • Newsroom
    • Press Releases
    • Capella (Scientific Presentations)
    • Media Kit
  • Investors

    Investors
    • Investors
    • Stock Information
    • Investors Toolkit
    • Events & Presentations
    • Financial Information
    • SEC Filings
    • Corporate Governance
    • Analyst Coverage
    • Fundamentals
    • Ownership Profile
    • Annual Meetings
    • Press Releases
    • Capella (Scientific Presentations)
    • FAQs
  • Medical Professionals

    Medical Professionals
    • For Medical Professionals
    • Genetic Testing & Counseling
    • Early Access Program
    • Medical Publication Support
    • Investigator Initiated Studies (IIS)
  • Patients

    Patients
    • For Patients
    • Amyloidosis
    • Acute Hepatic Porphyria
    • Primary Hyperoxaluria
    • Patient Services
    • Genetic Testing and Counseling
    • Patient Advocacy
  • Careers

    Careers
    • About Careers
    • Working at Alnylam
    • Search Jobs
    • Diversity, Equity & Inclusion
  • Quick Links

    Quick Links
    • Clinical Trials
    • Corporate Responsibility
    • Diversity, Equity & Inclusion
    • Press Releases
    • Capella (Scientific Presentations)
    • Medical Resources (RNAi Science)
    • Contact Us
  • Follow Us

    Follow Us
    • Youtube
    • Facebook
    • X
    • LinkedIn
    • Instagram
    • Sign Up

Our News

Share this:

Call for Entries: Deadline Extended - Submit Your Original Art Depicting Life with hATTR Amyloidosis

August 8, 2019

Alnylam Pharmaceuticals

“The Art of Living with hATTR Amyloidosis” is a new initiative inviting members of the hereditary ATTR (hATTR) amyloidosis community – including patients, caregivers, family members, and healthcare providers – to create and submit artistic representations expressing what it is like to live with the condition. The goal of the project is to raise awareness of hATTR amyloidosis – a rare, rapidly progressive and life-threatening disease – to help give voice to the community and support those who may feel isolated.

Symptoms of hATTR amyloidosis can vary and manifest differently, impacting multiple parts of the body and affecting people in distinct ways. This individualized experience can leave people feeling quite alone, and words can either be difficult to find or fall short in helping others to understand what each person is facing. ‘The Art of Living with hATTR Amyloidosis’ is designed to be a creative outlet for the community to share the diverse experiences of living with this this rare and sometimes misunderstood condition, to help raise awareness and change perspectives on it.

– Tiffany Patrick, Head of Global Patient Advocacy and Engagement at Alnylam

A panel of judges from the hATTR amyloidosis community and Alnylam will review submissions to select those which most effectively or creatively bring to life the impact of hATTR amyloidosis. Selected artwork will be featured in a printed calendar given to participants at the Amyloidosis Support Groups’ Biennial ATTR (Familial) Meeting, October 25 – 27, 2019 in Chicago, Illinois. The art may also be featured at other, future events, including symposiums, meetings in Alnylam’s offices, medical centers, and reproductions in the future. 

To participate, submit a photo of your original artwork to ArtofLiving@alnylam.com, along with your first name and location, by September 22, 2019. Please see below for full terms and conditions.

Terms and Conditions

By submitting a photo of your artwork (including drawings, paintings, photographs, mixed media and sculpture images) to Alnylam for selection and publication in a printed calendar, you agree to provide a permanent, non-exclusive, sublicensable, royalty-free license to display, publish, broadcast, reproduce, cache, and distribute this artwork in any medium. Artwork must be free of any rights of third parties. For photographs or any other media that include identifiable people, you must have the appropriate consent to submit the work in this contest. You will always retain ownership and copyright of your original artwork. Alnylam will never sell your artwork. 

Entries can be submitted by those impacted by hATTR amyloidosis, including patients, caregivers, family members, and healthcare providers. Entries will be judged based solely on the inspirational nature of their artwork, and not on the entrants’ use of specific treatment options.

“The Art of Living with hATTR Amyloidosis” initiative is open to legal residents of the 50 United States and the District of Columbia who are at least 18 years of age. The submission period opens at 12:00:00 AM (Midnight) Eastern Time ("ET") on August 8, 2019 and ends at 11:59:59 PM ET on September 22, 2019. Any photos of artwork submitted after this date will not be considered. Void outside the 50 United States and District of Columbia, and void where otherwise prohibited. Sponsored by Alnylam Pharmaceuticals, Inc. 300 Third Street, 3rd Floor, Cambridge, MA 02142.

All entrants must submit a photo of their artwork, along with their first name and location, to ArtofLiving@alnylam.com. Art will only be presented to the judging panel for selection if it conforms to predefined formats and dimensions required (see below).

  • Photos should be no larger than 8MB and no smaller than 3024x4032 pixels
  • For 3-D representations, such as sculpture, please submit at least two photos of the piece
  • JPG files are preferred, but PNG and TIF files will be accepted
  • Up to five pictures may be sent per entrant

 

Those who submit selected artwork will be notified via email. Respecting your privacy, selected artwork published in the calendar will include only your first name and city or state. For more details on Alnylam’s data privacy policy, please visit https://www.alnylam.com/privacy-policy/

If a person or a family portrayed in selected artwork no longer wishes the artwork to be used for public communication, Alnylam will discontinue further use. However, previously developed communication supports will be used until out of stock.

For any questions, please email ArtofLiving@alnylam.com

Tags

Patient Focus, Articles, hATTR amyloidosis, Patient Advocacy

Related Content See All News ›
Patient Focus Looking Beyond the Clinic: Putting Patients at the Center of Holistic Care in Transthyr ...
Patient Focus Alnylam’s Commitment to Health Literacy for All
Patient Focus First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR ...

Share this:

Categories

  • Leadership
  • Perspectives
  • RNAi
  • Patient Focus
  • Responsibility
  • Careers & Culture

Content Types

  • Articles
  • Podcasts
  • Presentations
  • Videos
See All News ›
Related Content See All News ›
Patient Focus Looking Beyond the Clinic: Putting Patients at the Center of Holistic Care in Transthyr ...
Patient Focus Alnylam’s Commitment to Health Literacy for All
Patient Focus First Consensus Recommendations for Holistic Care of People Living With Hereditary ATTR ...
See All News ›

FOLLOW US

Visit our social channels to learn more about the innovative work we are doing at Alnylam.

  • Our Company
  • Our Science
  • Our Products
  • Our News
  • Investors
  • Medical Professionals
  • Patients
  • Job Seekers
  • Clinical Trials
  • Corporate Responsibility
  • Diversity, Equity & Inclusion
  • Press Releases
  • Capella
  • Medical Resources (RNAi Science)
  • Contact Us
  • Sign Up For Updates
  • Privacy Policy
  • Media Kit
  • Legal Notice
  • Site Map
  • Sign Up For Updates

Copyright ©  Alnylam Pharmaceuticals, Inc. — All Rights Reserved

You are now leaving Alnylam.com

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site